Literature DB >> 29847306

Pyoderma Gangrenosum of the Breast After Mastopexy.

Zeina Asyyed, Sarah Al-Youha, Martin LeBlanc.   

Abstract

INTRODUCTION: Pyoderma gangrenosum (PG) is a rare, inflammatory, noninfectious skin disorder that is idiopathic in nature; however, it may occur as a rare complication of breast surgery. The mainstay of treatment is medical immunosuppression. CASE REPORT: This report describes the case of a 46-year-old woman who developed PG of both breasts following bilateral reduction mammoplasty and mastopexy. She was managed with a combination of medical immunotherapy and full-thickness skin grafts, which resulted in successful wound healing.
CONCLUSIONS: This patient's positive outcome illustrates the use of skin grafts in combination with medical immunotherapy in the setting of PG. This approach, which differs from the common method of treating solely with medical immunotherapy, may provide a quicker and more satisfying result for the patient.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29847306

Source DB:  PubMed          Journal:  Wounds        ISSN: 1044-7946            Impact factor:   1.546


  3 in total

Review 1.  Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases.

Authors:  Klaus Eisendle; Tobias Thuile; Jenny Deluca; Maria Pichler
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-04-28       Impact factor: 4.730

2.  Pyoderma Gangrenosum Masquerading as Necrotizing Infection after Autologous Breast Reconstruction.

Authors:  Tae Hwan Park; Kenneth L Fan; Elizabeth G Zolper; David H Song; Gabriel Del Corral
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-04-10

Review 3.  Dermatologic Complications Following Cosmetic and Reconstructive Plastic Surgery: A Systematic Review of the Literature.

Authors:  Peter J Nicksic; Rebecca L Farmer; Samuel O Poore; Venkat K Rao; Ahmed M Afifi
Journal:  Aesthetic Plast Surg       Date:  2021-07-06       Impact factor: 2.326

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.